Literature DB >> 8566628

Colonic mucosal changes in patients with liver cirrhosis.

T N Tam1, W W NG, S D Lee.   

Abstract

BACKGROUND: Portal colopathy has been reported in patients with cirrhosis of the liver. The aim of this study is to evaluate colonic mucosal changes and their clinical significance.
METHOD: Seventy-five cirrhotic patients with anemia and hemoccult-positive stool and 75 control subjects underwent endoscopic examinations of lower gastrointestinal tract. RESULT: Colonic ectasiae were found to be significantly more common in the 75 cirrhotic patients (80% with hepatitis B or C infection) than control subjects (84% vs 0, p < 0.0001). The lesions in 63 cirrhotic patients were found throughout the entire colon. They included colonic telangiectasiae or angiodysplastic-like lesions in 56 (89%) patients, red spots in 14 (22%), features suggesting mild chronic colitis in 8 (13%), and midrectal colorectal varices in 10 (16%). Pathologic findings in patients with telangiectasiae or angiodysplastic-like lesions showed dilation of vessels (7 of 9 patients) and edema of mucosa (6 of 9 patients). There was no correlation between the severity of cirrhosis, grade of esophageal varices, and the presence of colonic ectasiae.
CONCLUSIONS: Our observations demonstrate that colonic mucosal changes commonly occur in cirrhotic patients with viral hepatitis. The risk of intermittent hemorrhage from colonic ectasiae should be considered in cirrhotic patients with anemia but without evidence of upper gastrointestinal bleeding. These characteristic lesions may represent a spectrum of portal in hypertensive intestinal vasculopathy.

Entities:  

Mesh:

Year:  1995        PMID: 8566628     DOI: 10.1016/s0016-5107(95)70040-4

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  8 in total

Review 1.  Non-variceal gastrointestinal bleeding in patients with liver cirrhosis: a review.

Authors:  M Kalafateli; C K Triantos; V Nikolopoulou; A Burroughs
Journal:  Dig Dis Sci       Date:  2012-06-04       Impact factor: 3.199

Review 2.  Portal hypertensive enteropathy.

Authors:  Parit Mekaroonkamol; Robert Cohen; Saurabh Chawla
Journal:  World J Hepatol       Date:  2015-02-27

3.  Clostridium sp. bacteremia in a cirrhotic patient with an unresecable hepatocellular carcinoma: as fatal as we thought?

Authors:  Helena Masnou; Vicente Lorenzo-Zúñiga; Eva Erice Muñoz; Ramón Planas; Miquel Angel Gassull
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

4.  Increased prevalence of intestinal inflammation in patients with liver cirrhosis.

Authors:  Osamu Saitoh; Kazunori Sugi; Keishi Lojima; Hisashi Matsumoto; Ken Nakagawa; Masanobu Kayazawa; Seigou Tanaka; Tsutomu Teranishi; Ichiro Hirata
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

5.  Portal hypertensive colopathy in patients with liver cirrhosis.

Authors:  Keiichi Ito; Katsuya Shiraki; Takahisa Sakai; Hitoshi Yoshimura; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

Review 6.  Avoiding pitfalls: what an endoscopist should know in liver transplantation--part 1.

Authors:  Sharad Sharma; Ahmet Gurakar; Nicolas Jabbour
Journal:  Dig Dis Sci       Date:  2007-11-09       Impact factor: 3.199

7.  Portal hypertensive colopathy is associated with portal hypertension severity in cirrhotic patients.

Authors:  Antonio Diaz-Sanchez; Oscar Nuñez-Martinez; Cecilia Gonzalez-Asanza; Ana Matilla; Beatriz Merino; Diego Rincon; Inmaculada Beceiro; Maria Vega Catalina; Magdalena Salcedo; Rafael Bañares; Gerardo Clemente
Journal:  World J Gastroenterol       Date:  2009-10-14       Impact factor: 5.742

8.  Blood ammonia levels in liver cirrhosis: a clue for the presence of portosystemic collateral veins.

Authors:  Giovanni Tarantino; Vincenzo Citro; Pasquale Esposito; Sabrina Giaquinto; Annalisa de Leone; Graziella Milan; Francesca Saveria Tripodi; Michele Cirillo; Roberto Lobello
Journal:  BMC Gastroenterol       Date:  2009-03-17       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.